Wan Yuming, Huang Jing, Xu Feng
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhongguo Fei Ai Za Zhi. 2018 May 20;21(5):413-418. doi: 10.3779/j.issn.1009-3419.2018.05.10.
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure. This paper will review the definition, indication, dose regimens, dose-volume constraints for organs at risk, radiation technology, treatment side effect of centrally located NSCLC treated with SBRT and stereotactic body proton therapy.
一些研究已证明，对于医学上无法手术的Ⅰ期非小细胞肺癌（NSCLC）患者，约90%的局部控制率可能得益于立体定向体部放疗（SBRT），据报道SBRT相关的总生存率和肿瘤特异性生存率与手术治疗的患者相当。SBRT已被公认为无法手术的外周型Ⅰ期NSCLC患者的一线治疗方法。然而，由于相邻解剖结构存在潜在毒性作用，SBRT在中央型病变中的作用存在争议。本文将综述SBRT和立体定向体部质子治疗中央型NSCLC的定义、适应证、剂量方案、危及器官的剂量体积限制、放射技术、治疗副作用。
